This page is part of the MII IG Kerndatensatz-Modul Onkologie (v2027.0.0-ballot.1: Release) based on FHIR (HL7® FHIR® Standard) R4. This is the current published version in its permanent home (it will always be available at this URL). For a full list of available versions, see the Directory of published versions

• Narrative Content
• XML
• JSON

: mii-exa-onko-molecular-her2-alternatives

Raw json | Download

{
  "resourceType" : "RequestGroup",
  "id" : "mii-exa-onko-molecular-her2-alternatives",
  "meta" : {
    "profile" : [
      🔗 "https://www.medizininformatik-initiative.de/fhir/ext/modul-onko/StructureDefinition/mii-pr-onko-therapieempfehlung-kombinationstherapie|2027.0.0-ballot.1"
    ]
  },
  "language" : "en",
  "text" : {
    "status" : "generated",
    "div" : "<div xml:lang=\"en\" lang=\"en\"><hr/><p><b>English</b></p><hr/><p class=\"res-header-id\"><b>Generated Narrative: RequestGroup mii-exa-onko-molecular-her2-alternatives</b></p><a name=\"mii-exa-onko-molecular-her2-alternatives\"> </a><a name=\"hcmii-exa-onko-molecular-her2-alternatives\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-mii-pr-onko-therapieempfehlung-kombinationstherapie.html\">MII PR Onkologie Therapieempfehlung Kombinationstherapie</a> version: 2027.0.0-ballot.1</p></div><p><b>status</b>: Active</p><p><b>intent</b>: Proposal</p><p><b>code</b>: <span title=\"Codes:{https://www.medizininformatik-initiative.de/fhir/ext/modul-onko/CodeSystem/mii-cs-onko-therapie-typ ZS}\">HER2-gerichtete Therapie - Resistenz-basierte Auswahl</span></p><p><b>subject</b>: <a href=\"Patient-mii-exa-onko-molecular-board-patient.html\">Maria Müller  Female, DoB: 1968-07-22 ( https://www.medizininformatik-initiative.de/fhir/sid/patienten#MTB-2024-001)</a></p><p><b>authoredOn</b>: 2024-01-16</p><p><b>reasonReference</b>: <a href=\"Condition-primaertumor-example.html\">Condition Bösartige Neubildung: Brustdrüse, nicht näher bezeichnet</a></p><blockquote><p><b>action</b></p><p><b>title</b>: HER2-Therapie Optionen</p><p><b>description</b>: Auswahl basierend auf Resistenzprofil und klinischer Situation</p><p><b>selectionBehavior</b>: Any</p><p><b>requiredBehavior</b>: Must</p><h3>Actions</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Title</b></td><td><b>Resource</b></td></tr><tr><td style=\"display: none\">*</td><td>Zweite Linie: T-DM1</td><td><a href=\"MedicationRequest-mii-exa-onko-tdm1-option.html\">MedicationRequest: status = active; intent = option; medication[x] = Trastuzumab emtansin; authoredOn = 2024-01-16; note = Zweitlinien-Option, empfohlen bei Progression unter Trastuzumab-basierter Therapie</a></td></tr><tr><td style=\"display: none\">*</td><td>Dritte Linie: Tucatinib-Kombination</td><td><a href=\"MedicationRequest-mii-exa-onko-tucatinib-option.html\">MedicationRequest: status = active; intent = option; medication[x] = Tucatinib; authoredOn = 2024-01-16; note = Drittlinien-Kombination für Hirnmetastasen oder mehrfach resistente HER2+ Erkrankung</a></td></tr></table></blockquote></div>"
  },
  "status" : "active",
  "intent" : "proposal",
  "code" : {
    "coding" : [
      {
        "system" : "https://www.medizininformatik-initiative.de/fhir/ext/modul-onko/CodeSystem/mii-cs-onko-therapie-typ",
        "code" : "ZS"
      }
    ],
    "text" : "HER2-gerichtete Therapie - Resistenz-basierte Auswahl"
  },
  "subject" : {
    🔗 "reference" : "Patient/mii-exa-onko-molecular-board-patient"
  },
  "authoredOn" : "2024-01-16",
  "reasonReference" : [
    {
      🔗 "reference" : "Condition/primaertumor-example"
    }
  ],
  "action" : [
    {
      "title" : "HER2-Therapie Optionen",
      "description" : "Auswahl basierend auf Resistenzprofil und klinischer Situation",
      "selectionBehavior" : "any",
      "requiredBehavior" : "must",
      "action" : [
        {
          "title" : "Zweite Linie: T-DM1",
          "resource" : {
            🔗 "reference" : "MedicationRequest/mii-exa-onko-tdm1-option"
          }
        },
        {
          "title" : "Dritte Linie: Tucatinib-Kombination",
          "resource" : {
            🔗 "reference" : "MedicationRequest/mii-exa-onko-tucatinib-option"
          }
        }
      ]
    }
  ]
}